Clinical trials: Treatment Resistant Depressive Disorder
Obesity, Major Depressive Disorder
Comorbid Obesity and Depression With an Anti-inflammatory Medication
Research suggests that only a subset of individuals with major depressive disorder (MDD) may benefit from anti-inflammatory treatments: those who have C-reactive protein (CRP) ≥3 mg/L, a commonly used threshold for "low-grade"…
- Conditions
- Obesity, Major Depressive Disorder, Inflammation
- Trial name
- CODA (NCT06537921)
- Testing
- Minocycline 200mg
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- King's College London
Treatment Resistant Depression
Berlin Deep Brain Stimulation Depression Study
In this study efficacy and safety of deep brain stimulation of the cingulate cortex in 20 patients with treatment resistant major depression will be investigated.
- Trial name
- BDDS (NCT00531726)
- Testing
- DBS of Cg25
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Charite University, Berlin, Germany
Major Depression
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
The investigators plan to use optical brain imaging technology to observe patients with current major depression before, during, and after repetitive Transcranial Magnetic Stimulation (rTMS) clinical treatment.
- Trial name
- NCT01768052
- Testing
- functional Near Infrared Spectroscopy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
High Dose Accelerated iTBS for Depression
This trial will compare active intermittent theta burst stimulation (iTBS) rTMS in an accelerated treatment schedule (8 treatment sessions per day for 5 days) to a placebo control.
- Trial name
- NCT04255784
- Testing
- Active iTBS
- Where
- 2 sites in Canada
- Volunteers
- 228 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression
Deep Brain Stimulation to Relieve Depression
This is an open label study with a sample size of 6 to develop deep brain stimulation of the subcallosal cingulate white matter(SCCWM) for late life depression using an experimental medicine approach in which the investigators…
- Trial name
- DRIVER (NCT02889250)
- Testing
- Medtronic Activa SC DBS, Lead Model 3387
- Sponsor
- Jordan F. Karp
Depression
Buprenorphine for Late-Life Treatment Resistant Depression
The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.
- Trial name
- BUILD (NCT01071538)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pittsburgh
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study
The investigators propose a single-arm, open-label study to evaluate the effectiveness, safety, tolerability and feasibility of at-home transcranial direct current stimulation (tDCS) as a treatment for depression, particularly in…
- Trial name
- NCT07217223
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Ketamine Infusions for PTSD and Treatment-Resistant Depression
The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning.
- Trial name
- NCT02577250
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Major Depression
Use of Risperidone in ECT for Treatment Resistant Depression
The purpose of this study is to determine if the combination of risperidone and ECT improves a patient's response in depression compared to ECT alone.
- Trial name
- NCT00203723
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, Los Angeles
Depression
Aripiprazole as Augmentation for TRD
A sizeable minority of patients suffering from major depression do not have their full set of depressive symptoms relieved by a single medication.
- Trial name
- NCT00174876
- Testing
- Drug Abilify
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression
Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry.
- Trial name
- PReSiDio-BP (NCT07127913)
- Testing
- Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Andrew Krystal
Treatment Resistant Depression
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
The goal of this study is to use the Activa Primary Cell + Sensing (PC+S) device to study Latent Field Potential (LFP) in the brains of people with Treatment Resistant Depression (TRD) before and during active stimulation.
- Trial name
- NCT01984710
- Testing
- Medtronic Activa PC+S System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Bipolar Disorder, Treatment Resistant Depression
Implementation Trial of Evidence Based Practices for Mood Disorders
The objective of this Implementation Trial is to evaluate the implementation of evidence based practices for Bipolar Disorder and Treatment Resistant Depression in small rural Federally Qualified Health Centers.
- Trial name
- NCT02150577
- Testing
- Evidence Based Quality Improvement
- Where
- 6 sites in United States
- Volunteers
- 291 people
- Sponsor
- University of Arkansas
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Sevoflurane for Treatment-Resistant Depression
This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.
- Trial name
- NCT05008939
- Testing
- Sevoflurane
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Psychiatric Disorder, Major Depressive Disorder
Exploring Blood Plasma Metabolomics: Unraveling the Metabolic Landscape in Treatment-Resistant Adolescent Depression
This study contributes new evidence for the identification of adolescent TRD and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent TRD and FEDN-MDD.
- Conditions
- Psychiatric Disorder, Major Depressive Disorder, Metabolic Disorder
- Trial name
- NCT06331572
- Testing
- 17-HAMD
- Where
- China
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Treatment Resistant Depression (TRD)
Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.
Depression is the leading cause of disability worldwide. Major Depressive Disorder (MDD) is the most common diagnosis made for individuals seeking treatment for depression.
- Trial name
- NCT06729580
- Testing
- Behavioural Activation
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- McGill University
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Depressive Disorder, Schizophrenia
Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder
Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression, and is also useful in treatment-refractory cases of schizophrenia and obsessive compulsive disorder (OCD).
- Conditions
- Depressive Disorder, Schizophrenia, Schizoaffective Disorder, Obsessive-Compulsive Disorder
- Trial name
- NCT01596608
- Testing
- Magnetic Seizure Therapy (MagPro MST)
- Where
- Canada
- Volunteers
- 224 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression, Major Depressive Disorder
ECT vs. Esketamine
Treatment-resistant depression (TRD) is a common cause of disability and one of the most common psychiatric disorders worldwide. Electroconvulsive therapy (ECT) is currently the most effective treatment for TRD.
- Trial name
- ETES (NCT04924257)
- Testing
- Esketamine nasal spray, Electroconvulsive therapy
- Where
- Austria
- Sponsor
- Medical University Innsbruck